GLT8D1 and neoplasm: The variations in GATAD2A (c.A65G),GLT8D1 (c.C955G) and SLC25A39 (c.C809T) were validated in all sequenced cases both in non-tumor and tumor samples (Fig. 4 and Figure S4), showing that these variations were constitutive mutations.